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Abstract
Background: To identify whether early metabolic responses as determined using 18F-fluorodeoxyglucose positron
emission tomography/computed tomography (FDG PET/CT) during radiotherapy (RT) predict outcomes in patients
with esophageal cancer.
Methods: Twenty-one patients with esophageal cancer who received pre-treatment 18F-FDG PET/CT (PET1) and
inter-fractional 18F-FDG PET/CT (PET2) after 11 fractions of RT (median 23.1 Gy, 2.1 Gy per fraction) were retrospectively
reviewed. The region of interest for each calculation was delineated using “PET Edge”. We calculated PET parameters
including maximum and mean standardized uptake values (SUVmax and SUVmean, respectively), metabolic tumor volume
(MTV), and total lesion glycolysis (TLG). The relative changes (%) were calculated using the logarithmically transformed
parameter values for the PET1 and PET2 scans. Multivariate analysis of locoregional recurrence and distant failures were
performed using Cox regression analysis. After identifying statistically significant PET parameters for discriminating
responders from non-responders, receiver operating characteristics curve analyses were used to assess the potentials of
the studied PET parameters.
Results: After a median follow-up of 13 months, the 1-year overall and progression-free survival rates were 79.0%
and 34.4%, respectively. Four patients developed locoregional recurrences (LRRs) and 8 had distant metastases
(DMs). The 1-year overall LRR-free rate was 76.9% while the DM-free rate was 60.6%. The relative changes in MTV
(ΔMTV) were significantly associated with LRR (p = 0.03). Conversely, the relative changes in SUVmean (ΔSUVmean)
were associated with the risk of DM (p = 0.02). An ΔMTV threshold of 1.14 yielded a sensitivity of 60%, specificity
of 94%, and an accuracy of 86% for predicting an LRR. Additionally, a ΔSUVmean threshold of a 35% decrease
yielded a sensitivity of 67%, specificity of 83%, and accuracy of 76% for the prediction DM.
Trial registration: Retrospectively registered.
Conclusions: Changes in tumor metabolism during RT could be used to predict treatment responses, recurrences,
and prognoses in patients with esophageal cancer.
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Background
Cancer staging is currently the most important meas-
ure for predicting survival as well as for treatment
planning. The use of 18F-fluoro-2-deoxyglucose positron
emission tomography/computed tomography (18F-FDG
PET/CT) as an imaging modality has been steadily in-
creasing in patients with most types of solid tumors,
including esophageal cancer [1]. The use of FDG up-
take, which is indicative of tumor metabolism, has also
been explored for its prognostic utility. 18F-FDG PET/
CT-based metabolic parameters such as the standard-
ized uptake value (SUV) and total lesion glycolysis
(TLG) have been established and validated as surrogate
parameters for predicting survival in patients with
esophageal cancer [2, 3].
Additionally, 18F-FDG-PET/CT can be used to evalu-
ate treatment response by determining changes in tumor
glucose uptake following chemotherapy or radiotherapy
(RT). Several studies of patients with esophageal cancer
have indicated that tumor metabolic activity after pre-
operative treatment is strongly associated with histopatho-
logic responses and overall outcomes [4–7]. However,
such assessments usually provide information regarding
late treatment responses, the main drawback of which is
that physicians are unable to provide patients with nonre-
sponding tumors alternative treatment strategies during
the early stages of therapy. As such, other studies have
demonstrated satisfactory measurements of metabolic
parameters after only 2 weeks of induction therapy with
acceptable sensitivities and specificities, allowing for the
accurate early prediction of response to treatment in pa-
tients with esophageal cancer [8, 9]. To that end, 18F-FDG
PET/CT has been proposed for predicting early responses
and potentially allowing a change of individualized treat-
ment; however, this method has not yet been established
in routine clinical practice. Determining early responses
using 18F-FDG PET/CT would allow non-invasive stratifi-
cation of patients according to their responses and help
devise more effective treatment regimens. Most studies of
early responses using 18F-FDG PET/CT are limited to
patients treated with chemotherapy and not RT. Fur-
thermore, due to the radiation exposure during PET
scan [10], mid-radiotherapy PET scan has not been
widely adopted regardless of its clinical benefit. To
implement predictive 18F-FDG PET/CT-guided algo-
rithms for patients undergoing RT, the prognostic
values of early metabolic responses as well as specific
18F-FDG PET/CT-based metabolic parameters ought to
be determined in the setting of inter-fractional 18F-FDG
PET/CT (PET2) after the initiation of RT. Therefore, the
aim of this study was to investigate whether inter-fractional
metabolic response evaluation using 18F-FDG PET/CT
could be used as a predictor of RT response in patients with
esophageal cancer.
Materials and methods
Study population
Patients diagnosed with esophageal cancer who had under-
gone RT with PET2 between November 2015 and June
2017 were enrolled in this study. Patients were excluded if
pre-RT 18F-FDG PET/CT (PET1) was either not available
or performed at another institution (n = 4) or if they did
not complete RT (n = 2). Ultimately, we retrospectively
reviewed the medical records and tumor characteristics of
21 patients, as well as their clinical outcomes. This study
was approved by the Health Institutional Review Boards of
Yonsei University Hospital (IRB No. 2017-3510-001). The
requirement for informed consent was waived owing to the
study’s retrospective nature.
Treatment
Standard treatment at our center consists of 6 weeks of RT
with concurrent chemotherapy. Chemotherapy was admin-
istered to all patients using a 5-fluorouracil (5-FU) – based
regimen except in 3 patients who were medically ineligible
(2 underwent RT alone and 1 received uracil/tegafur).
Overall, 18 patients were treated with the 5-FU/cisplatin
regimen, 2 cycles of which were administered concurrently
during RT. Patients had a 4-week break after the comple-
tion of RT, and additional maintenance chemotherapy was
performed if a medical oncologist determined that the
patient’s performance status would allow for it. 5-FU was
administered at 500–1250mg/m2 daily as a continuous
infusion using a portable electronic pump on days 1–4,
while cisplatin was administered at 40–100mg/m2 on day
1 and during RT sessions.
The consistent RT technique used was as follows: The
gross tumor volume (GTV) was delineated using simula-
tion CT (3 mm slice thickness) and included the primary
tumor and involved regional nodes that were detected
via PET and CT fusion using the MIM software (Mim
Software Inc., Cleveland, OH, USA). The initial clinical
target volume included the GTV plus a margin of at
least 4 cm longitudinally and 2 cm radially. The final
planning target volume (PTV) was delineated by adding
a 0.3 cm margin to both the GTV and clinical target
volume based on our institutional image-guidance strat-
egies (PTV1 and PTV2, respectively). A total of 63 Gy in
30 fractions was prescribed to the PTV1 while 54 Gy in
30 fractions was prescribed to the PTV2 using simultan-
eous integrated boost for patients who underwent definite
chemoradiation therapy. For preoperative chemoradiation
therapy, a total of 44.1 Gy in 21 fractions and 37.8 Gy in
21 fractions were prescribed to the PTV1 and PTV2,
respectively. All patients received intensity-modulated
radiation therapy using volumetric modulated arc therapy.
Daily pre-treatment imaging using cone beam CT was
performed with corresponding position correction before
the delivery of each fraction.
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18F-FDG PET/CT method
18F-FDG PET/CT scans were performed with a PET-CT
scanner (Biograph TruePoint 40; Siemens Healthcare, Er-
langen, Germany). Prior to undergoing 18F-FDG PET/CT,
each patient fasted for a minimum of 6 h before 18F-FDG
administration, and the plasma glucose level was main-
tained below 140mg/dL. 18F-FDG was administered intra-
venously at an approximate dosage of 5.5MBq/kg of body
weight. After a tracer uptake time of median 58min (range,
45–63min), patients were subjected to PET/CT imaging; a
low-dose, non-contrast CT scan was obtained for attenu-
ation correction. The intrinsic spatial resolution of the sys-
tem was approximately 5mm (full-width at half-maximum)
in the center of the field of view. Images were acquired
from the skull base to the proximal thigh. PET images were
reconstructed using a 3D row-action maximum-likelihood
iterative reconstruction algorithm. To minimize the nega-
tive predictive value caused by non-specific FDG accu-
mulation in radiation mediated inflammatory lesion, we
performed 18F-FDG PET/CT assessment 2 weeks after
the initiation of treatment [11]. The reliability of the early
response evaluation 2 weeks after the initiation of treat-
ment has been identified by multiple series; it represents
the time course of RT response [8, 12]. The 18F-FDG
PET/CT examinations were performed within 1month
before the initiation of RT (PET1) and a median 11 (range,
9–12) days after RT (PET2).
PET metrics
Measurements of metabolic uptake in FDG-avid tumors
following pretreatment and inter-fractional scans were
compared and evaluated to predict the response to RT.
For analysis of PET metrics, all primary tumors were de-
fined as the region of interest and delineated on the PET1
and PET2 scans using PET Edge, a semi-automatic
gradient-based delineation method included in MIM soft-
ware, consistently by a single radiation oncologist (NLK).
This method algorithm places the contour boundary at
the location where the signal gradient is highest; it has
been found to correspond better to pathological speci-
mens than threshold-based methods [13] and has recently
been validated in a multi-observer study that showed
superiority over the manual and threshold methods in
non-small cell lung cancers [14].
The following quantitative features were extracted
from the regions of interest of the PET1 and PET2: max-
imum and mean SUVs (SUVmax and SUVmean, respect-
ively), metabolic tumor volume (MTV), and TLG. The
SUVmax was defined as the maximum activity concentra-
tion in the tumor/(injected dose/body weight). The SUV-
mean was defined as the mean concentration of FDG in the
tumor/(injected dose/body weight). The MTV was auto-
matically calculated by the software by summing the areas
with each 2-dimensional transverse tumor contour and
multiplying the values by the corresponding slice thick-
ness. The TLG was calculated by multiplying the SUVmean
by the MTV of the tumor [15].
Table 1 Patient and treatment characteristics
Number Percent
Patient characteristics
Age at treatment (yrs), median (range) 69.2 (46.4–
86.8)
Sex
Female 3 14.3
Male 18 85.7
ECOG PS
0–1 12 57.1
2 9 42.9
Pathology
Squamous cell carcinoma 21 100.0
Adenocarcinoma 0 0.0
Site
Upper thoracic (UI 20–25 cm) 5 23.8
Middle thoracic (UI 25–30 cm) 9 42.9
Lower thoracic (UI 30–40 cm) 7 33.3
Stage
I 1 4.8
IIB 4 19.0
IIIA 3 14.3
IIIB 7 33.3
IIIC 6 28.6
Treatment characteristics
Aim
Definitive 17 81.0
Preop 4 19.0
Concurrent chemotherapy 19 90.5
Chemotherapy regimen (n = 19)
5-Fluorouracil+cisplatin 18 94.7
5-Fluorouracil monotherapy 1 5.3
RT modality
IMRT 21 100.0
3D-CRT 0 0.0
Median total dose (Gy), median (range) 63 (44.1–
69.3)
Median fraction dose (Gy), median (range) 2.1 (1.8–2.1)
Fractions of RT completed before
mid-radiotherapy PET (fractions), median (range)
11 (9–12)
Dose of RT completed before
mid-radiotherapy PET (Gy), median (range)
23.1 (18.9–
25.2)
Abbreviations: ECOG PS Eastern Cooperative Oncology Group performance
status, UI upper incisor, RT radiotherapy, IMRT intensity-modulated
radiotherapy, 3D-CRT 3 dimensional-conformal radiotherapy
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Statistical analysis
The association between clinical outcomes and PET met-
rics was evaluated using the chi-square test for categorical
parameters and Student’s T-test for continuous parametric
parameters. Multiple PET parameters were logarithmically
transformed to meet the assumption of linearity on the
logit scale. The relative changes (%) were calculated using
the logarithmically transformed parameter values for the
PET1 and PET2 scans. Locoregional recurrence and distant
metastasis were defined as recurrence within and outside
the PTV, respectively. The time to events was measured
from the date of the first RT administration. The survival
curves were estimated using the Kaplan-Meier method
and compared using the log-rank test. Multivariate ana-
lysis of locoregional recurrence and distant failures were
performed using Cox regression analysis. After identify-
ing statistically significant PET parameters for discrimin-
ating responders from non-responders, receiver operating
characteristics curve analyses were used to assess the po-
tentials of the studied PET parameters; the sensitivity, spe-
cificity, accuracy, positive predictive value (PPV), and
negative predictive value (NPV) were calculated for an
optimal threshold that was determined by providing
equal weight to the sensitivity and specificity on the re-
ceiver operating characteristics curve. A p-value < 0.05
was considered statistically significant. Statistical analyses
were performed using SPSS version 23.0.0 (IBM Corp.,
Armonk, NY) and R version 3.3.0.
Results
Cohort characteristics
The patients’ characteristics are shown in Table 1. Most
subjects underwent definitive chemoradiation therapy
(n = 17, 81.0%). The PET2 was obtained approximately
2 weeks (median, 11 days) after the initiation of RT; the
median dose at the time of PET2 was 23.1 (range, 18.9–
25.2 ) Gy.
PET metrics
The median PET1 SUVmax and SUVmean were 15.1
(Interquartile range [IQR] 9.9–19.5) and 7.7 (IQR 5.8–
11.5), respectively. Furthermore, the median PET1 MTV
and TLG values were 10.2 (IQR 7.3–19.0) mL and 96.2
(IQR 39.7–346.3), respectively. The PET metrics were
generally lower on PET2 than on PET1; the per-patient
relative changes after RT according to 18F-FDG PET in-
tensity (SUVmax, SUVmean) and metabolic tumor volume
(MTV, TLG) are shown in Additional file 1: Table S1.
Treatment outcomes
The median follow-up was 13.1 (range, 1.6–23.6) months.
The 1-year overall survival (OS) and progression-free
survival (PFS) rates were 79.0% and 34.4%, respectively
(Fig. 1a). Four patients developed locoregional recurrences
and 8 showed distant metastases. The overall 1-year
locoregional recurrence-free rate (LRFR) was 76.9%,
while the distant metastasis-free rate (DMFR) was
60.6% (Fig. 1b).
Prognostic PET parameters
The relative changes to the MTV (i.e., ΔMTV) were sig-
nificantly associated with locoregional recurrence (haz-
ard ratio [HR] 0.98, 95% confidence interval [CI] 0.96–
1.00; p = 0.03, Table 2). Conversely, the relative changes
in the SUVmean (i.e., ΔSUVmean) were associated with the
risk of distant recurrence (HR 0.90, 95% CI 0.82–0.99;
Fig. 1 Clinical outcomes for the entire cohort. Progression-free survival, overall survival (a), locoregional recurrence-free rate (LRFR), and distant
metastasis-free rate (DMFR) (b) for the entire cohort
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p = 0.02, Table 2). However, neither initial GTV, mid-RT
GTV, nor relative changes to the GTV was associated
with locoregional recurrence or distant metastasis.
Good responders and non-responders
The optimal ΔMTV and ΔSUVmean cut-off values that dis-
criminated responders from non-responders were calcu-
lated as 1.14 (MTV PET2/MTV PET1) and − 35% (i.e., a
35% decrease), respectively.
The LRFR was more favorable in responders as deter-
mined by ΔMTV (n = 16, 76.2%) than in non-responders
(n = 5, 23.8%), with 1-year LRFRs of 92.3 and 0.0%, re-
spectively (p < 0.001, Fig. 2a). Distant metastasis was not
significantly different between these 2 groups; the 1-year
DMFRs were 60.3% vs. 75.0%, respectively (p = 0.896,
Fig. 2b).
Furthermore, the DMFR was better in responders as
determined by ΔSUVmean (n = 12, 57.1%) than in
Table 2 Predictors of locoregional recurrence and distant metastasis identified using a Cox proportional hazards model
Locoregional recurrence Distant metastasis
Univariate analysis Univariate analysis
HR 95% CI p value HR 95% CI p value
Patient factor
ECOG PS (0–1 vs. 2) 4.21 0.44–39.93 0.21 0.47 0.11–1.93 0.29
Stage
I – IIIA vs. IIIB, IIIC 49.49 0.01–180,664.89 0.35 0.67 0.15–2.94 0.59
PET1
SUVmax 0.96 0.81–1.13 0.62 0.95 0.84–1.07 0.37
SUVmean 0.89 0.63–1.25 0.49 0.85 0.66–1.09 0.21
MTVa 1.00 0.96–1.05 0.84 1.00 0.96–1.03 0.85
TLGa 1.00 1.00–1.00 0.93 1.00 1.00–1.00 0.59
GTVa 1.00 0.97–1.03 0.84 1.01 0.99–1.03 0.42
PET2
SUVmax 1.24 0.95–1.63 0.12 1.08 0.90–1.29 0.42
SUVmean 1.92 0.80–4.62 0.15 1.54 0.90–2.65 0.12
MTVa 1.02 0.96–1.09 0.48 1.01 0.95–1.06 0.80
TLGa 1.01 1.00–1.02 0.29 1.00 0.99–1.01 0.75
GTVa 0.99 0.94–1.04 0.64 1.02 0.99–1.05 0.17
Relative difference
ΔSUVmax 0.98 0.95–1.00 0.09 0.97 0.94–0.99 0.01
ΔSUVmean 0.98 0.95–1.01 0.18 0.95 0.91–0.98 0.00
ΔMTV 0.97 0.95–0.99 0.01 1.00 0.98–1.02 0.76
ΔTLG 0.98 0.96–0.99 0.01 0.98 0.96–1.00 0.04
ΔGTV 1.01 0.97–1.05 0.67 1.00 0.97–1.03 0.82
Locoregional recurrence Distant metastasis
Multivariate analysis Multivariate analysis
HR 95% CI p value HR 95% CI p value
Relative difference
ΔSUVmax 0.98 0.94–1.02 0.32 1.04 0.98–1.11 0.22
ΔSUVmean 0.90 0.82–0.99 0.02
ΔMTV 0.98 0.96–1.00 0.03
ΔTLG 1.24 0.80–1.56 0.12 1.00 0.98–1.02 0.75
The foreparts of the parentheses were set as the reference groups
Abbreviations: ECOG PS Eastern Cooperative Oncology Group performance status, SUVmax maximum standardized uptake value, SUVmean mean standardized uptake
value, MTV metabolic tumor volume, TLG total lesion glycolysis, HR hazard ratio, CI confidence interval
aLog transformed
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non-responders (n = 9, 42.9%); the 1-year DMFRs
were 83.3% vs. 31.1%, respectively (p = 0.011, Fig. 3b).
However, locoregional control was not significantly differ-
ent between the 2 groups; the 1-year LRFRs were 90.9%
and 63.5%, respectively (p = 0.226, Fig. 3a).
Based on the ΔMTV criteria, good responders (n =
16, 76.2%) showed longer PFS than non-responders
(n = 5, 23.8%), with 1-year PFS rates of 34.6 and 0%, re-
spectively (p < 0.001, Additional file 2: Figure S1). The
ΔMTV-based response criteria also exhibited borderline
significance for OS, as the 1-year OS rates were 85.7 and
60.0%, respectively (p = 0.051, Additional file 2: Figure S1).
On the other hand, there were no significant differences
in OS and PFS between good responders and
non-responders based on the ΔSUVmean criteria (Add-
itional file 3: Figure S2).
Diagnostic tests
The diagnostic test results are summarized in Table 3.
Using the calculated threshold of 1.14, the ΔMTV
yielded a sensitivity of 60%, specificity of 94%, accuracy
of 86%, PPV of 75%, and NPV of 88% for predicting
locoregional recurrence. Furthermore, the ΔSUVmean
yielded a sensitivity of 67%, specificity of 83%, accuracy
Fig. 2 Clinical outcomes according to the MTV change. Locoregional recurrence-free rate (a) and distant metastasis-free rate (b) of patients
according to the MTV reduction ratio (mid-treatment MTV-to-pretreatment MTV). Responders were patients with MTV reduction ratios ≤1.14;
while non-responders were patients with MTV reduction ratios > 1.14
Fig. 3 Clinical outcomes acoorindg to the SUVmean change. Locoregional recurrence-free rate (a) and distant metastasis-free rate (b) of patients
according to the mean standardized uptake value (SUVmean) reduction rate. Responders were patients with SUVmean reduction rates > 35%, while
non-responders were patients with SUVmean reduction rates ≤35%
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of 76%, PPV of 75%, and NPV of 77% for predicting dis-
tant metastasis when the calculated threshold of − 35%
was used.
Discussion
We examined the value of using 18F-FDG PET metrics
before and during chemoradiation in predicting responses
to treatment in patients with esophageal cancer. We cal-
culated an optimal cut-off value for ΔMTV (a ratio of
1.14), which was predictive of locoregional recurrence, as
well as a cut-off value for the ΔSUVmean (a 35% reduc-
tion), which was predictive of distant metastasis. These
factors showed satisfactory abilities to predict inadequate
responses to RT, indicating that the ΔMTV and ΔSUVmean
could be useful for identifying responders.
An accurate prediction of pathologic responses is critical,
since patients with poor responses are exposed to unneces-
sary treatment-related toxicities [16, 17]. Therefore, the pre-
dictive value of 18F-FDG PET/CT response during treatment
has been widely accepted in preoperative chemotherapy for
patients with esophageal cancer [9, 12, 18]. Previous
studies of 18F-FDG PET/CT before and after induction
chemotherapy found a significant association between
early metabolic response and histopathologic tumor re-
gression [19].
The early response appears to be an indicator of tumor
biology and a predictor of the likelihood of treatment failure.
As such, early response evaluation can help identify patients
who are eligible for treatment intensification or modifica-
tion, and thus reduce treatment failures in poor responders
(the so-called 18F-FDG PET/CT guided treatment
algorithm). The MUNICON trial prospectively confirmed
the feasibility and usefulness of the 18F-FDG PET/CT
guided treatment algorithm in patients with esopha-
geal cancer. Poor metabolic responders halted chemo-
therapy and switched to immediate surgery; such early
termination of chemotherapy based on metabolic re-
sponses did not negatively affect clinical outcome [9,
12].
Tumor stage, nodal stage, and patient characteristics
(including morphological information evaluated using
esophagoscopy and CT) were not statistically significant
prognostic factors on multivariate analysis in our study.
On the other hand, the changes in SUV or MTV in the
primary tumor, as measured by 18F-FDG PET/CT, are
dependent on glucose metabolism and reflect the changes
in tissue viability in response to chemoradiation. Notably,
other series that examined the prognostic value of PET
metrics in patients receiving chemotherapy and/or RT for
esophageal cancer identified different prognostic metrics,
ranging from SUVmax [20, 21] to a percentage decrease
in TLG [22], the percentage decrease in MTV and TLG
[23, 24], and the PET2-based MTV and TLG values
themselves [25]. However, there remain statistical concerns
such as multiple comparisons and selective reporting of
endpoints, because most of these studies were retrospective
and examined multiple outcomes. In our series, a small
decrease in PET2 MTV was associated with local recur-
rence, suggesting that this parameter may help select
patients that would benefit from further local RT dose
escalation. Another promising direction is to consider
early switching of systemic chemotherapy in patients
with a small decrease in SUVmean. Further investiga-
tions are required to determine whether additional sal-
vage strategies, such as early switching of concurrent
systemic therapy, would be beneficial.
Decrease in MTV represents volumetric changes in
the size of high metabolic tumor cells. Thus, it is rea-
sonable to suspect that ΔMTV after local radiotherapy
might be a more effective predictor than SUV values in
regards to locoregional recurrence [26, 27]. The SUV-
mean is the SUV value based on MTV. The SUVmean
represents the enhanced tapping of 18F-FDG into the
tumor cells due to biological mechanisms, tumor ag-
gressiveness, and hypoxia [28, 29]. Therefore it pro-
vides information of inherent tumor characteristics
which suggests a tendency to distant metastasis. In
addition, it is well known that the accuracy of CT for
assessment of extent in esophageal cancer is limited in
the determination of T status [30, 31]. It is the reason
why delineated gross tumor volume does not have its
prognostication ability.
Our study had several limitations. First, the results
should be interpreted with caution because this was a
retrospective analysis. Second, ours was a single-center
Table 3 Diagnostic tests for metabolic response criteria based
on MTV and SUVmean
Value (%) 95% CI (%)
MTV - Locoregional recurrence
Pretest probability 23.8 5.5 – 42.0
Sensitivity 60.0 17.1 – 102.9
Specificity 93.8 81.9 – 105.6
Diagnostic Accuracy 85.7 70.8 – 100.7
Positive Predictive Value 75.0 32.6 – 117.4
Negative Predictive Value 88.2 72.9 – 103.6
SUVmean - Distant metastasis
Pretest probability 42.9 21.7 – 64.0
Sensitivity 66.7 35.9 – 97.5
Specificity 83.3 62.3 – 104.4
Diagnostic Accuracy 76.2 58.0 – 94.4
Positive Predictive Value 75.0 45.0 – 105.0
Negative Predictive Value 76.9 54.0 – 99.8
Abbreviations: CI confidence interval, MTV metabolic tumor volume, SUVmean
mean standardized uptake value
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study, which would therefore carry inherent biases.
However, our analysis was strengthened by including all
possible PET metrics in our diagnostic tests using modern
18F-FDG PET/CT techniques and imaging analyses. Other
limiting factors include possible inflammatory changes
caused by irradiation, which may mimic changes in tumor
glucose metabolism associated with treatment effect [32].
Additionally, because of the partial-volume effect, tumor
shrinkage upon initiation of treatment may lead to under-
estimation of the FDG uptake observed on mid-treatment
18F-FDG PET/CT scans, and a consequent overestimation
of the change of parameters such as the SUV [2]. There
is also a possibility of errors introduced by calibration
of PET/CT which could the interpretation of SUV
make inaccurate [33]. While measuring changes in
FDG uptake is a widely adopted parameter that reflects
the proportion of viable tumor cells, the development
of additional new tracers specific to apoptosis and pro-
liferation may help provide an even more accurate pre-
diction of RT response.
Conclusion
We found the correlation between decrease in MTV
with locoregional recurrence and decrease in SUVmean
with distant metastasis, respectively, in esophageal can-
cer patients treated with chemoradiation therapy. The
optimal management of patients with poor responses
identified on inter-fractional 18F-FDG PET/CT remains
to be determined. Furthermore, a prospective study to
confirm the efficacy of 18F-FDG PET/CT-guided algo-
rithms in patients with esophageal cancer is warranted.
Additional files
Additional file 1: Table S1. Quantitative parameters on the pre-
treatment PET1 scan and inter-fractional PET2 scan. (DOCX 17 kb)
Additional file 2: Figure S1. Survival outcomes according to the MTV
change. Progression-free survival (A) and overall survival (B) of patients
according to the metabolic tumor volume (MTV) reduction ratio (mid-
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